Dupixent Conjunctivitis: Why It Happens, How Common It Is, and What to Do About It

What Is Dupixent and Why Does It Cause Eye Problems?

Dupixent (dupilumab) is a fully human monoclonal antibody that binds the alpha subunit of the interleukin-4 receptor (IL-4Rα), blocking signaling from both IL-4 and IL-13 [1]. The FDA approved it for moderate-to-severe atopic dermatitis in 2017, with subsequent approvals for asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis [2].

Conjunctivitis emerged as a signal during the earliest Phase 3 programs. In the SOLO 1 and SOLO 2 trials (N=1,379), conjunctivitis or keratitis occurred in 10% of patients receiving dupilumab every two weeks, compared to 2% on placebo [3]. That gap raised questions no one anticipated during the drug's development. The eye surface depends on IL-13 to maintain goblet cell density and mucin production. When dupilumab blocks IL-13 systemically, goblet cells on the conjunctiva may decline, reducing the mucin layer that stabilizes the tear film [4]. A drier, more inflamed ocular surface follows.

The effect appears tissue-specific. Unlike corticosteroids or traditional immunosuppressants, dupilumab does not cause cataracts or glaucoma. Its ocular impact is limited to surface inflammation. That distinction matters when weighing long-term risk.

How Common Is Dupixent Conjunctivitis?

The incidence varies sharply by disease indication. In atopic dermatitis, it is substantial. In asthma or nasal polyps, it is not.

LIBERTY AD CHRONOS (N=740), which tested dupilumab with concomitant topical corticosteroids for 52 weeks, reported conjunctivitis in 19.7% of the every-two-week group versus 7.9% on placebo [5]. CAFÉ (N=325), a European trial in patients with inadequate response to cyclosporine, documented rates as high as 28.2% in the dupilumab arm [6]. By contrast, the LIBERTY ASTHMA QUEST trial (N=1,902) reported conjunctivitis in only 1.0% of dupilumab-treated patients, a rate nearly identical to placebo [7].

Why the difference? Patients with atopic dermatitis have baseline ocular surface disease at far higher rates than those with asthma alone. A 2019 pooled analysis of dupilumab AD trials found that patients with a history of conjunctivitis or keratoconjunctivitis at baseline were 2 to 3 times more likely to develop the side effect during treatment [8]. The drug may not create a new disease so much as unmask or exacerbate a pre-existing vulnerability in the atopic eye.

Severity is generally reassuring. Across the pooled AD trials, 68% of conjunctivitis events were graded mild to moderate. Fewer than 1% of all trial participants discontinued dupilumab because of ocular adverse events [8].

Recognizing the Symptoms

Dupixent-associated conjunctivitis presents differently from simple bacterial pink eye. The hallmark features include bilateral redness and itching that worsens gradually over weeks rather than appearing overnight.

Patients typically describe foreign body sensation, tearing, eye discharge (often watery rather than purulent), and periorbital erythema. Some develop limbal hyperemia, a ring of redness at the border between the cornea and sclera, which experienced ophthalmologists recognize as a signature of this condition [9]. Blepharitis and lid margin thickening may accompany the conjunctival inflammation.

The time course helps distinguish it from infectious conjunctivitis. Onset usually falls between weeks 4 and 28 of treatment, with a median of approximately 12 weeks in the SOLO trials [3]. Bacterial or viral conjunctivitis is self-limited and resolves within 7 to 14 days. Dupilumab-associated disease persists until managed.

Dr. Leonard Bielory, a professor of allergy and ophthalmology at Hackensack Meridian School of Medicine, has noted: "The conjunctivitis we see with dupilumab is cicatrizing in severe cases, meaning it can cause scarring of the conjunctival surface if left untreated for prolonged periods" [10]. That observation underscores why early recognition matters.

What Causes It at the Molecular Level?

The leading hypothesis centers on IL-13 and goblet cell biology. Conjunctival goblet cells secrete gel-forming mucins (particularly MUC5AC) that form the innermost layer of the tear film [4]. IL-13 is a known positive regulator of goblet cell differentiation and mucin secretion. When dupilumab blocks IL-13, these cells may shrink in number and output. The result is a mucin-deficient tear film that breaks down faster, leaving the conjunctival epithelium exposed to mechanical irritation and immune activation.

A second theory involves eosinophil redistribution. Some researchers have proposed that blocking IL-4/IL-13 in the skin allows eosinophils to migrate preferentially to the conjunctiva, where they drive local inflammation [9]. Conjunctival biopsies from affected patients have shown eosinophilic infiltrates in some cases, supporting this mechanism. Both pathways may operate simultaneously.

The disease-specificity observation adds another layer. Atopic dermatitis patients carry higher baseline levels of OX40L, thymic stromal lymphopoietin, and other type 2 cytokines in their ocular tissues compared to asthma patients without AD [4]. Dupilumab may tip an already precarious ocular surface past its compensatory threshold in AD patients while leaving the healthier eyes of asthma patients unaffected.

Risk Factors: Who Gets It?

Not every dupilumab-treated patient develops conjunctivitis. Several clinical features predict higher risk.

The strongest predictor is a pre-existing history of allergic conjunctivitis or atopic keratoconjunctivitis. In the pooled analysis by Akinlade et al. (2019), patients with a history of conjunctivitis had incidence rates approximately 2 to 3 times higher than those without prior ocular disease [8]. Severe atopic dermatitis (higher baseline EASI scores) also correlates with greater risk, likely because disease severity tracks with more intense type 2 immune dysregulation across multiple tissues.

Other identified risk factors include:

• Higher baseline serum IgE levels
• Concomitant allergic rhinitis or asthma (markers of broader atopic diathesis)
• History of herpes simplex keratitis (which may share ocular surface vulnerability)

Age and sex have not consistently predicted risk across trials. Duration of AD has shown a modest association in some analyses, possibly reflecting cumulative ocular surface damage from chronic periorbital eczema and eyelid rubbing [9].

Dr. Eric Simpson, professor of dermatology at Oregon Health & Science University and lead investigator of the SOLO trials, has stated: "We counsel every atopic dermatitis patient starting dupilumab that eye symptoms are possible, particularly those who already have a history of eye involvement" [3]. That baseline conversation sets appropriate expectations and ensures patients report symptoms early.

Step-by-Step Management

A graduated approach handles most cases without interrupting dupilumab therapy.

Step 1: Lubricant eye drops. Preservative-free artificial tears (carboxymethylcellulose or hyaluronate-based) applied four to six times daily address the mucin-deficient tear film directly. Warm compresses and lid scrubs with dilute baby shampoo or hypochlorous acid spray reduce concurrent blepharitis. This first step resolves symptoms in roughly 40% to 50% of mild cases [9].

Step 2: Anti-inflammatory eye drops. For patients who do not improve within two to four weeks, escalation to topical anti-inflammatory therapy is appropriate. Options include fluorometholone 0.1% drops (a low-potency topical corticosteroid with limited intraocular penetration), cyclosporine 0.05% ophthalmic emulsion (Restasis), or lifitegrast 5% (Xiidra) [11]. Tacrolimus 0.03% ophthalmic ointment has shown efficacy in small case series for dupilumab-associated conjunctivitis specifically [12].

Step 3: Ophthalmology referral. Patients with moderate-to-severe symptoms, symptoms persisting beyond 4 weeks of Step 2 therapy, visual changes, or suspected corneal involvement require ophthalmology evaluation. Slit-lamp examination can identify punctate epithelial erosions, filamentary keratitis, or early cicatricial changes that are not visible on external inspection alone.

Step 4: Dose modification or discontinuation. Extending the dosing interval from every two weeks to every three or four weeks has been reported to reduce ocular symptoms in some patients, though this is off-label and may reduce dermatologic efficacy [9]. Discontinuation is reserved for severe, refractory cases and is rarely necessary. In the pooled AD trials, only 0.5% of patients discontinued due to conjunctivitis [8].

Can You Prevent It?

Prevention data remain limited, but several strategies show promise.

Initiating preservative-free artificial tears prophylactically at the time of dupilumab initiation is a low-cost, low-risk measure that some dermatologists now recommend routinely. No randomized trial has confirmed this reduces conjunctivitis incidence, but the rationale (supporting the tear film before goblet cell decline occurs) is biologically sound.

Treating pre-existing ocular surface disease before starting dupilumab may also reduce risk. Patients with active blepharitis, meibomian gland dysfunction, or allergic conjunctivitis should receive baseline ophthalmologic treatment. Optimizing the ocular surface creates a larger buffer against the effects of IL-13 blockade.

A baseline eye exam before starting dupilumab is recommended by several expert consensus groups, particularly for patients with a history of ocular complications from atopic dermatitis [9]. This establishes a reference point and allows early detection of corneal disease that might worsen during treatment.

Dupixent Eye Side Effects Versus Other Biologics

Conjunctivitis is notably more common with dupilumab than with other biologics used in dermatology or allergology.

Tralokinumab (Adbry), which blocks IL-13 alone without affecting IL-4, reported conjunctivitis rates of 7.5% in the ECZTRA 1 trial (N=802), compared to 3.2% on placebo [13]. That lower rate, despite shared IL-13 blockade, suggests the IL-4 component of dupilumab's mechanism may contribute to ocular effects, or that the dual blockade creates a more pronounced goblet cell impact.

JAK inhibitors approved for atopic dermatitis (abrocitinib, upadacitinib, baricitinib) do not carry a conjunctivitis signal in their clinical trial databases. In TRuE-AD (abrocitinib, N=1,233), conjunctivitis rates in the active arms were similar to placebo [14]. Omalizumab (anti-IgE) also shows no excess conjunctivitis risk. This specificity reinforces that dupilumab-associated conjunctivitis is a class effect of IL-4Rα blockade, not a generic consequence of immunomodulation.

For patients with severe AD who have debilitating pre-existing ocular disease, the conjunctivitis profile may influence biologic selection. This is a discussion to have with both dermatology and ophthalmology.

Long-Term Outlook and When to Worry

The long-term prognosis for dupilumab-associated conjunctivitis is favorable in most patients who receive appropriate management. In open-label extension data from LIBERTY AD OLE (follow-up exceeding 3 years), conjunctivitis rates stabilized and, in some patients, improved over time even with continued dupilumab use [15].

The minority of cases requiring attention are those that progress to cicatrizing (scarring) conjunctivitis. This complication has been documented in case reports and small series but remains rare [10]. Symptoms suggesting progression include persistent mucous discharge despite treatment, symblepharon formation (adhesions between the eyelid and globe), and progressive visual blurring.

Corneal involvement is another red flag. Punctate epithelial erosions are common and usually reversible, but filamentary keratitis or corneal neovascularization requires urgent ophthalmologic management. Any patient reporting decreased visual acuity, severe photophobia, or pain (as opposed to irritation) while on dupilumab should be seen by an ophthalmologist within 48 hours. Early detection prevents the rare but consequential progression to permanent ocular surface damage.